Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves Forward [Yahoo! Finance]
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.xenon-pharma.com
Company Research
Source: Yahoo! Finance
Xenon Pharmaceuticals climbed by 31.7 percent week-on-week, as investor sentiment was bolstered by positive clinical trial for its epilepsy and depression treatment candidate, alongside plans to submit a new drug application (NDA) in the second half of the year. In a statement earlier in the week, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) said that it would submit an NDA for its treatment candidate, Azetukalner, with the Food and Drug Administration (FDA) in the third quarter. Xenon Pharmaceuticals Climbs 31.7% as Epilepsy Treatment Moves Forward Jirsak/Shutterstock.com This followed the completion of the third phase of clinical trial, which saw a 53 percent seizure reduction in patients who took both 25mg and 15mg, versus the placebo, over a 12-week period. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) added that Azetukalner also demonstrated a safety and tolerability profile consistent with prior studies. “We are very happy to announce these data for azetukalner, which exceed
Show less
Read more
Impact Snapshot
Event Time:
XENE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XENE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENE alerts
High impacting Xenon Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
XENE
News
- Xenon Pharmaceuticals (XENE) had its price target lowered by Wedbush from $64.00 to $63.00. They now have an "outperform" rating on the stock.MarketBeat
- Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- Assessing Xenon Pharmaceuticals (XENE) Valuation After A Sharp Recent Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight [Yahoo! Finance]Yahoo! Finance
XENE
Earnings
- 2/26/26 - Miss
XENE
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- XENE's page on the SEC website